Dana-Farber Cancer Institute

https://www.dana-farber.org/

 

Gynecologic
07:23

SGO 2023 Conference Coverage on VuMedi

SGO 2023 Phase 1 Trial of Botensilimab + Balstilimab in Patients With Recurrent Platinum Refractory/Resistant Ovarian Cancer

FEATURING Bruno Bockorny
  • 83 views
  • April 14, 2023
  • 2
33:45

Dana-Farber Cancer Institute

Lynch Syndrome and Gynecologic Cancer Risk (and Risk Reduction)

FEATURING Marcela G. del Carmen
  • 84 views
  • January 5, 2019
  • 1